Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexible-dose oral semaglutide vs sitagliptin in type 2 diabetes (52-week trial with 52-week extension)
2015-005593-38Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Primary efficacy endpoint (main phase) and Primary safety endpoint (main phase). Started Jun 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005593-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005593-38.